CELZ$0.6377+2.28%
Creative Medical Technology Holdings, Inc.
Sector: Biological Products, (No Diagnostic Substances)Industry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$4.84M
Float & O/S:
Inst Own:
DilutionScan read 28 of CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s SEC filings and found 20 warrant series, 4 shelf registrations, 2 S-1 registrations and 3 completed offerings on file for CELZ. The latest dilution event on file is an offering on Sep 24, 2026. Analysis updated Oct 12, 2026.
Signal8 Summary
CELZ
Tight cash runway and heavy dilution
Snapshot
This is a pre-revenue biotechnology company burning cash rapidly. With only $6K in revenue for FY 2025 against a $6M net loss, the business relies entirely on external capital. The company holds $7.2M in cash but burns roughly $5.9M annually, leaving a tight cash runway of about 7.4 months.
What's Happening Right Now
- : The company received a Notice of Allowance for a new U.S. patent covering exosome-based immunotherapy for Type 1 Diabetes.
- : A proxy statement seeks approval to increase authorized shares four-fold and exercise warrants that would dilute existing shareholders by over 100%.
- : The company entered agreements for the immediate exercise of warrants expected to generate $4.5 million in gross proceeds.
- : The FDA cleared an expansion of the ADAPT trial evaluating CELZ-201 for chronic lower back pain.
